LBPH - Longboard Pharmaceuticals reports FY 2022 results March, 02 2023 04:35 PM Longboard Pharmaceuticals Inc. Longboard Pharmaceuticals press release ( NASDAQ: LBPH ): FY GAAP EPS of -$2.56 beats by $0.03 . Co currently estimates 2023 operating expenses in the $57.0 to $63.0 million range. For further details see: Longboard Pharmaceuticals reports FY 2022 results